Perfusion solution in glass vial, sterile and apyrogenic, isotonic with blood. Composed of Sodium chloride g 5.0, Potassium chloride g 0.75, Calcium chloride g 0.35, Magnesium chloride g 0.31, Sodium acetate g 6.40, Sodium citrate g 0.75, Water for prep. injection as required. Indicated for fluid and electrolyte replenishment and for the treatment of mild to moderate but not severe states of acidosis.
500 ml bottle

Perfusion solution in glass vial, sterile and apyrogenic, isotonic with blood. Composed of Sodium chloride g 5.0, Potassium chloride g 0.75, Calcium chloride g 0.35, Magnesium chloride g 0.31, Sodium acetate g 6.40, Sodium citrate g 0.75, Water for prep. injection as required. Indicated for fluid and electrolyte replenishment and for the treatment of mild to moderate but not severe states of acidosis.
500 ml bottle

Emergency treatment of allergic reactions to insect bites, food, drugs and other allergens in patients with an established risk of anaphylactic shock. FASTJEKT is an initial intervention product and does not replace subsequent medical treatment.

Emergency treatment of allergic reactions to insect bites, food, drugs and other allergens in patients with an established risk of anaphylactic shock. FASTJEKT is an initial intervention product and does not replace subsequent medical treatment.

Glucose solution for injection, sterile and apyrogenic. Available in 5% and 33%. Indicated for conditions requiring restoration of hydration in combination with caloric intake, especially in patients who do not require salts or where salts should be avoided, for restoring blood glucose concentrations in cases of hypoglycaemia. Low-concentration glucose solutions (5%-10%) may also be used as diluent solutions for the preparation of parenteral medicinal solutions or suspensions, as indicated in the Summary of Product Characteristics of the medicinal product to be administered.

Solution for intravenous infusion. Rehydrating and/or energising. Format: 10 x 500 ml bottles.

Glucose solution for injection, sterile and apyrogenic. Available in 5% and 33%. Indicated for conditions requiring restoration of hydration in combination with caloric intake, especially in patients who do not require salts or where salts should be avoided, for restoring blood glucose concentrations in cases of hypoglycaemia. Low-concentration glucose solutions (5%-10%) may also be used as diluent solutions for the preparation of parenteral medicinal solutions or suspensions, as indicated in the Summary of Product Characteristics of the medicinal product to be administered.

Glucose solution for injection, sterile and apyrogenic. Available in 5% and 10%. Indicated for conditions requiring restoration of hydration in combination with caloric intake, especially in patients who do not require salts or where salts should be avoided, for restoring blood glucose concentrations in cases of hypoglycaemia. Low-concentration glucose solutions (5%-10%) may also be used as diluent solutions for the preparation of parenteral medicinal solutions or suspensions, as indicated in the Summary of Product Characteristics of the medicinal product to be administered.

Tad contains glutathione (GSH), a physiological tripeptide composed of glutamic acid, cysteine and glycine, which is involved in numerous biological processes and plays an important role in the reactions that eliminate toxic substances from the body. Parenterally administered glutathione belongs to the pharmacotherapeutic category of antidotes, substances capable of transforming a toxic agent into a harmless or low-injury compound.

Tad is used for the prevention of neuropathy (disease of the nervous system) resulting from treatment with drugs called chemotherapeutics, such as cisplatin or analogues, used to treat certain types of cancer.

The medicinal product must be administered by intravenous infusion.
Treatment of isotonic fluid depletion (extracellular dehydration).
Adults and adolescents: 500 ml to 3 litres over 24 hours.
Infants and children (up to 12 years of age): 20 to 100 ml over 24 hours per kg body weight, depending on age and total body weight.
The dosage should be reduced appropriately in patients with renal insufficiency.
Treatment of sodium deficiency.